(Adnkronos) - “Nel 2023 abbiamo investito in ricerca e sviluppo 30,5 miliardi di dollari, 105 milioni di euro in Italia sui complessivi 700 dell’intero settore. Siamo decisamente favorevoli alla volontà politica di includere nella Legge di Bilancio e, quindi, nel fondo per i farmaci innovativi, anche l’innovatività condizionata. Ma si può migliorare anche togliendo il limite dei sei anni”. Lo ha detto Nicoletta Luppi, presidente e amministratrice delegata di Msd Italia, a Roma, in occasione del Convegno sul contributo dell’innovazone per il trattamento del tumore al polmone.
Category
🗞
NewsTranscript
00:00The commitment of MSD to counter the lung tumor is a commitment at 360 degrees, which starts
00:12from a research that has meant for the entire scientific community a revolution in the paradigm
00:19of care, and we are talking about immuno-oncology.
00:23Speaking of the lung tumor, there have been several studies aimed at capturing the possible
00:30nuances, the possible differences from patient to patient, and the type of tumor itself.
00:36And this is why the research has not stopped with respect to the first indication related
00:42to the study of Kynote 189, but has gone on with ever more encouraging news and more
00:48life and quality of life for many more patients.
00:52And this is why our country must be conducive to innovation, as we say, it must stimulate
01:00that innovation and that research so that it can bring more and more answers to the many
01:05patients who, unfortunately, have to go against this important health problem.
01:11And this is why, on our part as MSD, we are not tired of researching and investing heavily
01:18in research.
01:19We are the first biopharmaceutical company in the world for research intensity, 42% of
01:25our revenue, which means more than 30 billion dollars of research invested in research and
01:31development, which also equate to our 105 million euros, which are very important as
01:38they are compared to a total of 700 million euros invested in research and development
01:42by the entire pharmaceutical sector in Italy.
01:46As a company on its own, we really invest a lot.
01:49What does this mean?
01:51It means, as an innovation, access to innovation immediately for patients and, above all,
01:57opportunities to really be included in what is the great engine of research.
02:03The position of MSD and the opinion of MSD with respect to the balance sheet is certainly
02:08generally favorable because we continue to go in the right direction, that is, the increase
02:13of the national health fund.
02:16This increase responds to many needs, which are important needs, because unfortunately
02:22Italy, despite the recent increases in the national health fund, is far behind in terms
02:28of health investment per individual citizen compared to other countries such as France,
02:34Spain, Germany, and so on.
02:36As regards, in particular, the fund of innovative pharmaceuticals, we have welcomed with great
02:43favor the good news of the desire to include also the conditioned innovativeness and also
02:49the reserve antibiotics, which are certainly also another of the pillars of the research
02:54towards which we invest in an important way.
02:57However, it can certainly be perfected because, as often happens, there are particular rules
03:05that go to vanish the great effort that is wanted to be made to include also the
03:09conditioned innovativeness, and I am referring, in particular, to that six-year limit, beyond
03:15which, regardless of the goodness of the success of the research, we can no longer count in
03:22us, but above all the patients, on the possibility of accessing the innovative fund.
03:27This is not right because it is not right and above all it makes no sense, there is no
03:32scientific rationale in setting a time limit to research.
03:37Progressive research must move forward, and therefore it is not clear why it must reward
03:43what is innovative within the first six years and then arbitrarily, after six years, this
03:50should not happen.
03:51So, we hope that this norm will be expectably either abolished or at least extended until
03:58ten years, so that there is also an incentive, even for highly innovative companies like
04:03ours, to invest in clinical research even beyond the sixth year, with respect to the
04:09life of the product itself.